Cipla’s Revlimid Settlement Offers Date-Certain US Launch

Deal With Bristol Myers Squibb's Celgene Allows Initial ‘Limited’ Volumes

Cipla has become the latest generics firm to settle US patent litigation with Bristol Myers Squibb’s Celgene over its Revlimid blockbuster.

Handshake
Cipla and Bristol Myers Squibb's Celgene have settled over Revlimid • Source: Shutterstock

Cipla has become the latest in a line of generics firms to settle US patent litigation over Revlimid (lenalidomide) with Bristol Myers Squibb’s Celgene, gaining a date-certain launch for limited volumes of the multiple myeloma treatment followed by a later opportunity to launch an unlimited supply.

Noting that it will be able to market “volume-limited amounts of generic lenalidomide in the US beginning on a confidential...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business